![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer’s Xeljanz Approved For Active Polyarticular-Course Juvenile Idiopathic Arthritis
Pfizer’s Xeljanz Approved For Active Polyarticular-Course Juvenile Idiopathic Arthritis
September 30, 2020
The FDA has approved Pfizer’s Xeljanz (tofacitinib) in tablet and an oral solution for the treatment of children and adolescents with active polyarticular-course juvenile idiopathic arthritis (pcJIA).
The approval was based on positive results from a phase 3 clinical trial which found that the occurrence of disease flare-ups in patients treated with Xeljanz was lower than those given a placebo.
Pfizer anticipates that the oral solution will be available in the first quarter of next year. The 5 mg tablets are already available.
Upcoming Events
-
21Oct